HUYABIO's HBI-8000 Plus Nivolumab Delivers 58% Improvement in Progression-Free Survival in Phase 3 Advanced Melanoma Trial
核心洞察
The global Phase 3 HBI-8000-303 trial met its primary endpoint, showing a statistically significant 58% improvement in progression-free survival for HBI-8000 plus nivolumab versus nivolumab plus placebo.
Median progression-free survival reached 11.7 months with the combination compared to 7.4 months in the control arm, positioning the regimen as a potential new frontline treatment option.
The randomized trial enrolled 404 patients across 15 countries, representing HUYABIO's largest oncology study to date.
HUYABIO International (搜索) today announced statistically significant and clinically meaningful topline results from its global Phase 3 clinical trial evaluating HBI-8000 in combination with nivolumab for patients with advanced melanoma (搜索), bringing the company one step closer to a potential new frontline treatment option for one of the deadliest forms of skin cancer.
The study, designated HBI-8000-303, met its primary endpoint, with patients receiving HBI-8000 in combination with nivolumab achieving a median progression-free survival of 11.7 months, compared with 7.4 months for patients receiving nivolumab plus placebo — a statistically significant improvement in progression-free survival of 58%. Further statistical analysis is in progress to identify in detail the strong efficacy advantage of HBI-8000.
"These results represent an exciting milestone for patients and the future of melanoma treatment," said Dr. Mireille Gillings, CEO & Executive Chair of HUYABIO. "Although immunotherapy has dramatically improved outcomes, many patients still need better options. We believe HBI-8000 will become an important addition to the standard of care, helping physicians improve outcomes while bringing new hope to patients and their families."
Trial Design and Scope
The randomized global Phase 3 trial enrolled 404 patients across 15 countries, representing HUYABIO's largest oncology study to date. The trial compared HBI-8000 in combination with nivolumab against nivolumab plus placebo in the frontline setting for advanced melanoma (搜索).
HBI-8000: Established Safety Profile
HBI-8000 is an oral drug that has received regulatory approval for lymphoma (搜索) in both China and Japan. With prescriptions to over 90,000 patients, the drug has a well-established safety record, which may offer reassurance as the company pursues an expanded indication in advanced melanoma (搜索).
Next Steps
Data from the HBI-8000-303 trial will be presented at future medical meetings, where the full efficacy and safety dataset is expected to be shared with the oncology community. The positive topline results position HUYABIO to potentially seek regulatory discussions for a frontline melanoma indication, though the company has not yet disclosed specific regulatory timelines.